Covista earnings release, May 7, 2026

Covista Inc. (CVSA) · Form 8-K, Item 2.02 · Filed · SEC filing

​

Investor Contact:

Jeremy Cohen

Investor.Relations@Covista.com

+1 312-906-6600

​

Media Contact:

Maureen Bender

CovistaMedia@Covista.com

+1 313-319-4732

Covista Third Quarter Fiscal Year 2026 Results;

Raises Fiscal Year 2026 Revenue and Adjusted Earnings Per Share Guidance

Total enrollment up 6.8% YoY, with Chamberlain returning to positive total enrollment growth

Surpassed 100,000 students including record enrollment at Chamberlain and Walden

Revenue up 4.5% YoY; revenue up 8.4% YoY when adjusted for Walden one-week academic shift

Third quarter highlights

Capital allocation

Increased fiscal year 2026 guidance

​

CHICAGO – May 7, 2026 – Covista Inc. (NYSE: CVSA), the largest healthcare educator in the United States, today reported third quarter fiscal year 2026 results (ended Mar. 31, 2026). The Company continues to execute on its Growth with Purpose strategy, leading the transformation of higher education by training the next generation of healthcare professionals at an industry-leading scale.

“The country needs more nurses, physicians, and behavioral health professionals than the current system is on pace to produce. Covista is helping close that gap. This quarter shows the strength of our model: more than 100,000 students and growth across every segment, including a return to enrollment growth at Chamberlain,” said Steve Beard, Chairman and Chief Executive Officer, Covista. “We educate practitioners, and we are increasingly connecting them to the healthcare systems that need them most. We are raising guidance because execution is translating into results. The need is urgent, our role is clear, and the opportunity ahead is significant.”

Financial Highlights

Selected financial data for the three months ended Mar. 31, 2026:

​

Business Highlights

Segment Highlights

Chamberlain

​

​

Walden

​

​

Medical and Veterinary

​

​

Fiscal Year 2026 Outlook

Covista raised its revenue guidance for fiscal year 2026 from a range of $1,900 million to $1,940 million, or approximately 6% to 8.5% growth year-over-year, to a range of $1,930 million to $1,945 million, or approximately 8% to 9% growth year-over-year. Covista also raised its adjusted earnings per share guidance from a range of $7.80 to $8.00, or approximately 17% to 20% growth year-over-year, to a range of $7.95 to $8.15, or approximately 19% to 22% growth year-over-year.

​

Conference Call and Webcast Information

Covista will hold a conference call to discuss its third quarter fiscal year 2026 results today at 4:00 p.m. CT (5:00 p.m. ET).

​

The call can be accessed by dialing +1 877-407-6184 (U.S. participants) or +1 201-389-0877 (international participants) and stating “Covista earnings call” or by using conference ID:13759299. The call will be simulcast through the Covista investor relations website at: https://investors.covista.com.

​

Covista will archive a replay of the call for 30 days. To access the replay, dial +1 877-660-6853 (U.S.) or +1 201-612-7415 (international), conference ID: 13759299, or visit the Covista investor relations website.

​

About Covista

Covista (NYSE: CVSA) is America's largest healthcare educator, serving more than 100,000 students and supported by a community of 385,000 alumni across five accredited institutions. Through personalized, tech-enabled education powered by 10,000 faculty and colleagues, Covista expands access to healthcare careers and addresses the U.S. healthcare workforce shortage at scale. Covista is the parent company of American University of the Caribbean School of Medicine, Chamberlain University, Ross University School of Medicine, Ross University School of Veterinary Medicine and Walden University. For more information, visit Covista.com and follow us on

LinkedIn,

Instagram and

YouTube.

​

Financial statements

Income Statement

Three Months Ended — Chamberlain (in millions)

Three Months Ended – March 31, – 2026Three Months Ended – March 31, – 2025Three Months Ended – March 31, – % Change
Revenue197192.62.3%
Operating Income47.747.50.4%
Adj. Operating Income47.947.50.8%
Adj. EBITDA58.556.82.9%
Total Students (2)40,76740,5640.5%

Income Statement

Three Months Ended — Walden (in millions)

Three Months Ended – March 31, – 2026Three Months Ended – March 31, – 2025Three Months Ended – March 31, – % Change
Revenue186.6178.44.6%
Operating Income39.545.2-12.5%
Adj. Operating Income42.448-11.7%
Adj. EBITDA49.754-7.9%
Total Students (2)54,47448,52612.3%

Income Statement

Three Months Ended — Medical and Veterinary (in millions)

Three Months Ended – March 31, – 2026Three Months Ended – March 31, – 2025Three Months Ended – March 31, – % Change
Revenue103.5958.9%
Operating Income21.117.818.7%
Adj. Operating Income21.517.920.0%
Adj. EBITDA27.522.920.1%
Total Students (2)5,3445,1334.1%

Income Statement

Three Months Ended — (in thousands, except per share data)

Three Months Ended – March 31, – 2026Three Months Ended – March 31, – 2025Nine Months Ended – March 31, – 2026Nine Months Ended – March 31, – 2025
Revenue487,030466,0551,452,7031,331,184
Operating cost and expense:Cost of educational services210,719199,869616,911572,500
Operating cost and expense:Student services and administrative expense184,106175,167542,631491,141
Operating cost and expense:Restructuring expense8635105,2282,926
Operating cost and expense:Total operating cost and expense395,688375,5461,164,7701,066,567
Operating cost and expense:Operating income91,34290,509287,933264,617
Operating cost and expense:Interest expense-13,629-13,074-35,636-41,465
Operating cost and expense:Other income, net2321,8984,4226,779
Operating cost and expense:Income from continuing operations before income taxes77,94579,333256,719229,931
Operating cost and expense:Provision for income taxes-19,963-18,539-61,504-51,716
Operating cost and expense:Income from continuing operations57,98260,794195,215178,215
Discontinued operations:(Loss) income from discontinued operations before income taxes-21,86052-20,8106,216
Discontinued operations:Benefit from (provision for) income taxes5,515-145,440-1,578
Discontinued operations:(Loss) income from discontinued operations-16,34538-15,3704,638
Discontinued operations:Net income and comprehensive income41,63760,832179,845182,853
Basic:Continuing operations1.691.645.524.76
Basic:Discontinued operations-0.480-0.430.12
Basic:Total basic earnings per share1.211.645.084.88
Diluted:Continuing operations1.671.595.424.62
Diluted:Discontinued operations-0.470-0.430.12
Diluted:Total diluted earnings per share1.21.594.994.74
Weighted-average shares outstanding:Basic shares34,28337,14035,38137,434
Weighted-average shares outstanding:Diluted shares34,78238,23336,03138,583

Income Statement

Three Months Ended — (in thousands)

Three Months Ended – March 31, – 2026Three Months Ended – March 31, – 2025Three Months Ended – March 31, – Increase/(Decrease) – $$Three Months Ended – March 31, – Increase/(Decrease) – %Nine Months Ended – March 31, – 2026Nine Months Ended – March 31, – 2025Nine Months Ended – March 31, – Increase/(Decrease) – $$Nine Months Ended – March 31, – Increase/(Decrease) – %
Chamberlain:Operating income47,69647,5161800.4%105,302115,716-10,414-9.0%
Chamberlain:Restructuring expense199-232222,0241,912112
Chamberlain:Adjusted operating income47,89547,4934020.8%107,326117,628-10,302-8.8%
Chamberlain:Operating margin24.2%24.7%18.8%21.4%
Chamberlain:Adjusted operating margin24.3%24.7%19.2%21.7%
Walden:Operating income39,54045,194-5,654-12.5%168,035133,92934,10625.5%
Walden:Restructuring expense3131460460
Walden:Amortization of acquired intangible assets2,8052,8058,4158,415
Walden:Litigation reserve-5,5505,550
Walden:Adjusted operating income (1)42,37647,999-5,623-11.7%176,910136,79440,11629.3%
Walden:Operating margin21.2%25.3%28.3%26.2%
Walden:Adjusted operating margin (1)22.7%26.9%29.8%26.8%
Medical and Veterinary:Operating income21,12717,8003,32718.7%62,45453,9348,52015.8%
Medical and Veterinary:Restructuring expense375121254855236619
Medical and Veterinary:Adjusted operating income21,50217,9213,58120.0%63,30954,1709,13916.9%
Medical and Veterinary:Operating margin20.4%18.7%20.9%19.4%
Medical and Veterinary:Adjusted operating margin20.8%18.9%21.2%19.5%
Home Office:Operating loss-17,021-20,0012,98014.9%-47,858-38,962-8,896-22.8%
Home Office:Restructuring expense258412-1541,8897781,111
Home Office:Asset impairments6,442-6,4426,442-6,442
Home Office:Strategic advisory costs7,2385,1002,13817,0325,10011,932
Home Office:Debt modification costs712-712
Home Office:Adjusted operating loss-9,525-8,047-1,478-18.4%-28,937-25,930-3,007-11.6%

Income Statement

Three Months Ended — (in thousands)

Three Months Ended – March 31, – 2026Three Months Ended – March 31, – 2025Three Months Ended – March 31, – Increase/(Decrease) – $$Three Months Ended – March 31, – Increase/(Decrease) – %Nine Months Ended – March 31, – 2026Nine Months Ended – March 31, – 2025Nine Months Ended – March 31, – Increase/(Decrease) – $$Nine Months Ended – March 31, – Increase/(Decrease) – %
Chamberlain:Adjusted operating income (GAAP)47,89547,4934020.8%107,326117,628-10,302-8.8%
Chamberlain:Depreciation6,0275,35067717,10816,184924
Chamberlain:Amortization of cloud computing implementation assets2,0737861,2875,6202,2533,367
Chamberlain:Stock-based compensation2,4653,178-7138,70910,290-1,581
Chamberlain:Adjusted EBITDA (non-GAAP)58,46056,8071,6532.9%138,763146,355-7,592-5.2%
Chamberlain:Adjusted EBITDA margin (non-GAAP)29.7%29.5%24.8%27.0%
Walden:Adjusted operating income (GAAP)42,37647,999-5,623-11.7%176,910136,79440,11629.3%
Walden:Depreciation2,0751,9511246,0895,428661
Walden:Amortization of cloud computing implementation assets1,9187631,1555,0232,2422,781
Walden:Stock-based compensation3,3743,2888610,2649,354910
Walden:Adjusted EBITDA (non-GAAP) (1)49,74354,001-4,258-7.9%198,286153,81844,46828.9%
Walden:Adjusted EBITDA margin (non-GAAP) (1)26.7%30.3%33.4%30.1%
Medical and Veterinary:Adjusted operating income (GAAP)21,50217,9213,58120.0%63,30954,1709,13916.9%
Medical and Veterinary:Depreciation3,1092,7853248,9368,098838
Medical and Veterinary:Amortization of cloud computing implementation assets7203044161,836902934
Medical and Veterinary:Stock-based compensation2,1291,8482816,2215,613608
Medical and Veterinary:Adjusted EBITDA (non-GAAP)27,46022,8584,60220.1%80,30268,78311,51916.7%
Medical and Veterinary:Adjusted EBITDA margin (non-GAAP)26.5%24.0%26.9%24.7%
Home Office:Adjusted operating loss-9,525-8,047-1,478-18.4%-28,937-25,930-3,007-11.6%
Home Office:Depreciation166188-22494557-63
Home Office:Stock-based compensation1,6031,949-3465,9095,924-15
Home Office:Adjusted EBITDA-7,756-5,910-1,846-31.2%-22,534-19,449-3,085-15.9%
Covista:Net income (GAAP)41,63760,832-19,195-31.6%179,845182,853-3,008-1.6%
Covista:Loss (income) from discontinued operations16,345-3816,38315,370-4,63820,008
Covista:Interest expense13,62913,07455535,63641,465-5,829
Covista:Other income, net-232-1,8981,666-4,422-6,7792,357
Covista:Provision for income taxes19,96318,5391,42461,50451,7169,788
Covista:Depreciation and amortization18,89314,9323,96153,52144,0799,442
Covista:Stock-based compensation9,57110,263-69231,10331,181-78
Covista:Restructuring expense8635103535,2282,9262,302
Covista:Litigation reserve-5,5505,550
Covista:Asset impairments6,442-6,4426,442-6,442
Covista:Strategic advisory costs7,2385,1002,13817,0325,10011,932
Covista:Debt modification costs712-712
Covista:Adjusted EBITDA (non-GAAP) (1)127,907127,7561510.1%394,817349,50745,31013.0%
Covista:Adjusted EBITDA margin (non-GAAP) (1)26.3%27.4%27.2%26.3%

Income Statement

Three Months Ended — (in thousands, except per share data)

Three Months Ended – March 31, – 2026Three Months Ended – March 31, – 2025Nine Months Ended – March 31, – 2026Nine Months Ended – March 31, – 2025
Diluted earnings per share (GAAP)1.21.594.994.74
Effect on diluted earnings per share:Restructuring expense0.020.010.150.08
Effect on diluted earnings per share:Amortization of acquired intangible assets0.080.070.230.22
Effect on diluted earnings per share:Strategic advisory costs0.210.130.470.13
Effect on diluted earnings per share:Loss on debt extinguishment, litigation reserve, asset impairments, and debt modification costs0.110.210.130.09
Effect on diluted earnings per share:Income tax impact on non-GAAP adjustments (1)-0.11-0.11-0.24-0.12
Effect on diluted earnings per share:Loss (income) from discontinued operations0.4700.43-0.12
Effect on diluted earnings per share:Adjusted earnings per share (non-GAAP)1.981.926.165.01

Income Statement

Twelve Months Ended — (in thousands)

Twelve Months Ended – March 31, 2026March 31, 2026
Covista:Net income (GAAP)234,057
Covista:Loss from discontinued operations15,620
Covista:Interest expense46,489
Covista:Other income, net-6,933
Covista:Provision for income taxes75,625
Covista:Depreciation and amortization68,607
Covista:Stock-based compensation41,512
Covista:Restructuring expense5,616
Covista:Strategic advisory costs23,932
Covista:Loss on assets held for sale490
Covista:Adjusted EBITDA (non-GAAP)505,015
Covista:Long-term debt510,000
Covista:Less: Cash and cash equivalents-146,977
Covista:Net debt (non-GAAP)363,023
Covista:Net leverage (non-GAAP)0.7 x

Balance Sheet

(in thousands)

March 31, – 2026June 30, – 2025
Current assets:Cash and cash equivalents146,977199,601
Current assets:Restricted cash1,8621,563
Current assets:Accounts and financing receivables, net175,924146,189
Current assets:Prepaid expenses and other current assets78,99268,837
Current assets:Total current assets403,755416,190
Noncurrent assets:Property and equipment, net276,972256,131
Noncurrent assets:Operating lease assets201,079191,194
Noncurrent assets:Deferred income taxes32,956
Noncurrent assets:Intangible assets, net757,059765,474
Noncurrent assets:Goodwill961,262961,262
Noncurrent assets:Other assets, net137,300129,145
Noncurrent assets:Total noncurrent assets2,333,6722,336,162
Noncurrent assets:Total assets2,737,4272,752,352
Current liabilities:Accounts payable97,261105,017
Current liabilities:Accrued payroll and benefits75,09376,374
Current liabilities:Accrued liabilities92,84677,286
Current liabilities:Deferred revenue276,192214,091
Current liabilities:Current operating lease liabilities35,23035,159
Current liabilities:Current portion of long-term debt3,825
Current liabilities:Total current liabilities580,447507,927
Noncurrent liabilities:Long-term debt495,644552,669
Noncurrent liabilities:Long-term operating lease liabilities201,595186,172
Noncurrent liabilities:Deferred income taxes58,73131,856
Noncurrent liabilities:Other liabilities36,90540,103
Noncurrent liabilities:Total noncurrent liabilities792,875810,800
Noncurrent liabilities:Total liabilities1,373,3221,318,727
Commitments and contingenciesTotal shareholders' equity1,364,1051,433,625
Commitments and contingenciesTotal liabilities and shareholders' equity2,737,4272,752,352

Cash Flow

Nine Months Ended — (in thousands)

Nine Months Ended – March 31, – 2026Nine Months Ended – March 31, – 2025
Operating activities:Net income179,845182,853
Operating activities:Loss (income) from discontinued operations15,370-4,638
Operating activities:Income from continuing operations195,215178,215
Adjustments to reconcile net income to net cash provided by operating activities:Stock-based compensation31,10331,181
Adjustments to reconcile net income to net cash provided by operating activities:Amortization and impairments to operating lease assets21,00425,330
Adjustments to reconcile net income to net cash provided by operating activities:Depreciation32,62730,267
Adjustments to reconcile net income to net cash provided by operating activities:Amortization of acquired intangible assets8,4158,415
Adjustments to reconcile net income to net cash provided by operating activities:Amortization and write-off of debt discount and issuance costs6,9614,995
Adjustments to reconcile net income to net cash provided by operating activities:Provision for bad debts48,85346,854
Adjustments to reconcile net income to net cash provided by operating activities:Deferred income taxes65,31819,994
Adjustments to reconcile net income to net cash provided by operating activities:Loss on disposals and impairments of property and equipment6052,522
Adjustments to reconcile net income to net cash provided by operating activities:Gain on investments-561-268
Changes in assets and liabilities:Accounts and financing receivables-76,271-80,613
Changes in assets and liabilities:Prepaid expenses and other current assets-8965,727
Changes in assets and liabilities:Cloud computing implementation assets-10,087-21,959
Changes in assets and liabilities:Accounts payable-12,607-9,978
Changes in assets and liabilities:Accrued payroll and benefits-1,1361,406
Changes in assets and liabilities:Accrued liabilities-10,168-10,449
Changes in assets and liabilities:Deferred revenue66,32266,081
Changes in assets and liabilities:Operating lease liabilities-15,395-17,839
Changes in assets and liabilities:Other assets and liabilities-2,888-6,068
Changes in assets and liabilities:Net cash provided by operating activities-continuing operations346,414273,813
Changes in assets and liabilities:Net cash provided by operating activities-discontinued operations454,394
Changes in assets and liabilities:Net cash provided by operating activities346,459278,207
Investing activities:Capital expenditures-50,882-31,337
Investing activities:Proceeds from sales of marketable securities2,3143,120
Investing activities:Purchases of marketable securities-2,313-2,048
Investing activities:Payment for investment in business-5,000
Investing activities:Net cash used in investing activities-55,881-30,265
Financing activities:Proceeds from exercise of stock options13110,008

Cash Flow

Twelve Months Ended — (in thousands)

Twelve Months Ended – FY25 – Q3Twelve Months Ended – FY25 – Q4Twelve Months Ended – FY26 – Q1Twelve Months Ended – FY26 – Q2Twelve Months Ended – FY26 – Q3
Net cash provided by operating activities-continuing operations (GAAP)335,069333,734374,796427,890406,335
Capital expenditures-47,914-50,327-55,936-59,880-69,872
Free cash flow (non-GAAP)287,155283,407318,860368,010336,463
Full release

Cautionary Disclosure Regarding Forward-Looking Statements

Certain statements contained in this release are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, which includes statements regarding Covista’s future growth. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “future,” “believe,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “may,” “will,” “would,” “could,” “can,” “continue,” “preliminary,” “potential,” “range,” and similar terms. These forward-looking statements are subject to risk and uncertainties that could cause actual results to differ materially from those described in the statements. Important factors that could cause actual results to differ materially from the expectations expressed or implied by our forward-looking statements are disclosed in Item 1A. “Risk Factors,” of our Annual Report on Form 10-K. You should evaluate forward-looking statements in the context of these risks and uncertainties and are cautioned to not place undue reliance on such forward-looking statements. We caution you that these factors, performance or developments we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our operations in the way we expect. All forward-looking statements are based on information available to use as of the date any such statements are made, and Covista assumes no obligation to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized, except as required by law.

​... (truncated).

###

​

​

Covista Inc.

Consolidated Balance Sheets

(unaudited)

(in thousands)

​

​

​

​

Covista Inc.

Consolidated Statements of Income

(unaudited)

(in thousands, except per share data)

​

​

​

​

​

Covista Inc.

Consolidated Statements of Cash Flows

(unaudited)

(in thousands)

​

​

​

​

​

Covista Inc.

Segment Revenue

(unaudited)

(in thousands)

​

​

Covista Inc.

Non-GAAP Financial Measures and Reconciliations

We believe that certain non-GAAP financial measures provide investors with useful supplemental information regarding the underlying business trends and performance of Covista’s ongoing operations as seen through the eyes of management and are useful for period-over-period comparisons. We use these supplemental non-GAAP financial measures internally in our assessment of performance and budgeting process. However, these non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. The following are non-GAAP financial measures used in the subsequent GAAP to non-GAAP reconciliation tables:

Adjusted net income (most comparable GAAP measure: net income) – Measure of Covista’s net income adjusted for restructuring expense, amortization of acquired intangible assets, strategic advisory costs, loss on debt extinguishment, litigation reserve, asset impairments, debt modification costs, and loss (income) from discontinued operations.

Adjusted earnings per share (most comparable GAAP measure: diluted earnings per share) – Measure of Covista’s diluted earnings per share adjusted for restructuring expense, amortization of acquired intangible assets, strategic advisory costs, loss on debt extinguishment, litigation reserve, asset impairments, debt modification costs, and loss (income) from discontinued operations.

Adjusted operating income (most comparable GAAP measure: operating income) – Measure of Covista’s operating income adjusted for restructuring expense, amortization of acquired intangible assets, litigation reserve, asset impairments, strategic advisory costs, and debt modification costs.

Adjusted EBITDA (most comparable GAAP measure: net income) – Measure of Covista’s net income adjusted for loss (income) from discontinued operations, interest expense, other income, net, provision for income taxes, depreciation, amortization of acquired intangible assets, amortization of cloud computing implementation assets, stock-based compensation, restructuring expense, litigation reserve, asset impairments, strategic advisory costs, and debt modification costs. Provision for income taxes, interest expense, and other income, net are not recorded at the reportable segments, and therefore, the segment adjusted EBITDA reconciliations begin with adjusted operating income.

Free cash flow (most comparable GAAP measure: net cash provided by operating activities-continuing operations) – Defined as net cash provided by operating activities-continuing operations less capital expenditures.

Net debt – Defined as long-term debt less cash and cash equivalents.

Net leverage – Defined as net debt divided by adjusted EBITDA.

A description of special items in our non-GAAP financial measures described above are as follows:

Covista Inc.

Adjusted Operating Income

(unaudited)

(in thousands)

​

​

​

​

Covista Inc.

Adjusted EBITDA

(unaudited)

(in thousands)

​

​

Covista Inc.

Adjusted Earnings

(unaudited)

(in thousands, except per share data)

​

​

Note: May not sum due to rounding.

​

Covista Inc.

Free Cash Flow

(unaudited)

(in thousands)

​

​

​

​

Covista Inc.

Net Leverage

(unaudited)

(in thousands)

​

​

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Covista earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.